使-

Seyed Farzad Baniahmad1,2, Romane Oliverio3,4, Ines Obregon-Gomez5

  • 1Department of Biochemistry and Molecular Medicine, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

mAbs
|June 10, 2023
PubMed
概括

工程可以持续提供治疗性抗体. 标有Ecoil的trastuzumab (一种单克隆抗体) 证明了从水凝中制造和控制释放的可制造性.